Tandem Diabetes Care Overview
Valuation check: TNDM's ROE is -48.56%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-48.56%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Tandem Diabetes Care (TNDM) currently reports a ROE of -48.56%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Tandem Diabetes Care's ROE history and peer comparisons.
Tandem Diabetes Care's ROE of -48.56% is lower than the Healthcare sector average of 21.28%. That is roughly 328.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Tandem Diabetes Care's current -48.56% should be judged against Healthcare norms (sector average: 21.28%) and against TNDM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -48.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Tandem Diabetes Care, and consider following TNDM for alerts when major investors trade the stock.
Tandem Diabetes Care is classified in the Healthcare sector. On ROE, it currently shows -48.56% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TNDM with unrelated industries.
